title: Prevalence of remission and recovery in schizophrenia in the Czech Republic.
abstract: OBJECTIVE
  The aim of the study was to map the point prevalence of remission and recovery in patients with schizophrenia in the Czech Republic.
  
  
  METHODS
  The point-symptomatic remission criteria were based on the definition of remission in schizophrenia according to Andreasen, without the time criterion. The definition of complete remission contained, in addition to the point-symptomatic remission criteria, a time aspect which was determined by the absence of psychiatric hospitalisation or a change in antipsychotic medications due to inefficiency in the preceding six months. Functional remission was defined by a total score on the PSP scale in the range between 71 and 100 points. Recovery was defined by the simultaneous fulfilment of the criteria for complete and functional remission.
  
  
  RESULTS
  A total of 481 patients with schizophrenia were included in the study. The point-symptomatic remission criteria were fulfilled in a total of 258 patients (54%); complete remission occurred in a total of 214 patients (44%). Functional remission was reached by 124 patients (26%) in total. Recovery was proven in a total of 91 patients (19%).
  
  
  CONCLUSIONS
  The ascertained data are in accordance with the results of methodologically similar studies and confirm the known trajectories of the course of schizophrenia.
authors.affiliation: CEITEC - Central European Institute of Technology, Masaryk University, Brno, Czech Republic; Department of Psychiatry, Masaryk University, Faculty of Medicine and University Hospital Brno, Brno, Czech Republic. Electronic address: radovan.prikryl@post.cz.
authors.forename: Radovan
authors.initials: R
authors.lastname: Prikryl
authors.forename: Miroslava
authors.initials: M
authors.lastname: Kholova
authors.forename: Hana Prikrylova
authors.initials: HP
authors.lastname: Kucerova
authors.forename: Eva
authors.initials: E
authors.lastname: Ceskova
mesh_terms: D000328:Adult; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D003430:Cross-Sectional Studies; D018153:Czech Republic; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D015995:Prevalence; D011788:Quality of Life; D012008:Recurrence; D012074:Remission Induction; D012559:Schizophrenia / Q000188:drug therapy*; D012565:Schizophrenic Psychology; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D014150:Antipsychotic Agents